Evaluating guidelines on continuation of anti-tumour necrosis factor treatment after 3 months: clinical effectiveness and costs of observed care and different alternative strategies.
Ann Rheum Dis
; 68(6): 844-9, 2009 Jun.
Article
em En
| MEDLINE
| ID: mdl-18625616
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Artrite Reumatoide
/
Fator de Necrose Tumoral alfa
/
Seleção de Pacientes
/
Antirreumáticos
/
Anticorpos Monoclonais
Tipo de estudo:
Clinical_trials
/
Evaluation_studies
/
Guideline
/
Health_economic_evaluation
/
Observational_studies
/
Prognostic_studies
Limite:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Ano de publicação:
2009
Tipo de documento:
Article